Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)
ChromaDex Corporation (CDXC)
NASDAQ:AMEX Investor Relations:
investors.chromadex.com
Company Research
Source: Business Wire
This award recognizes Dr. Nkrumah-Elie’s dedication to advancing scientific excellence for ChromaDex’s leading external research program and mentorship in the dietary supplement industry LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced today that Radicle Science and Council for Responsible Nutrition (CRN) honored Yasmeen Nkrumah-Elie, Ph.D, ChromaDex’s Global Director of External Research, as the winner of the inaugural Trailblazing Woman Award.This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241015810330/en/Yasmeen Nkrumah-Elie, Ph.D accepts the Trailblazing Woman Award on stage during CRN’s CONVERGENCE Conference (Photo: Business Wire)“I am deeply honored to receive the Trailblazing Woman Award,” said Dr. Nkrumah-Elie, “and I am moved by the collective force of inspiring women leading within our
Show less
Read more
Impact Snapshot
Event Time:
CDXC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CDXC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CDXC alerts
High impacting ChromaDex Corporation news events
Weekly update
A roundup of the hottest topics
CDXC
News
- ChromaDex Co. (NASDAQ: CDXC) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- What Makes ChromaDex (CDXC) a Strong Momentum Stock: Buy Now? [Yahoo! Finance]Yahoo! Finance
- 5 Stocks With Recent Price Strength to Tap Wall Street Rally [Yahoo! Finance]Yahoo! Finance
- ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide [Yahoo! Finance]Yahoo! Finance
- ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics NationwideBusiness Wire
CDXC
Earnings
- 10/31/24 - Beat
CDXC
Sec Filings
- 11/8/24 - Form 3
- 10/31/24 - Form 8-K
- 10/31/24 - Form 10-Q
- CDXC's page on the SEC website